Suppr超能文献

感染风险低作为有效免疫的标志是否预示着随后发生巨细胞动脉炎或风湿性多肌痛的风险增加?一项基于丹麦人群的病例对照研究。

Does low risk of infections as a marker of effective immunity predict increased risk of subsequent giant cell arteritis or polymyalgia rheumatica? A Danish population-based case-control study.

作者信息

Brault Clément, Riis Anders H, Mor Anil, Duhaut Pierre, Thomsen Reimar W

机构信息

Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark,

Department of Internal Medicine and RECIF, Amiens-Picardie University Hospital, Amiens, France,

出版信息

Clin Epidemiol. 2018 Oct 16;10:1533-1543. doi: 10.2147/CLEP.S158293. eCollection 2018.

Abstract

OBJECTIVE

It has been suggested that a hyper-effective immune system ("hyper-immunity") is central to the pathogenesis of giant cell arteritis and polymyalgia rheumatica (GCA/PMR). We examined if a low risk of infections, as a marker of hyper-immunity, can predict increased subsequent risk of GCA/PMR.

PATIENTS AND METHODS

We conducted a population-based case-control study including all patients aged ≥50 years with incident GCA/PMR diagnosed between 1997 and 2012 in Northern Denmark. For each case, we selected 10 population controls matched on gender, age, place of residence, and time spent in the region. Complete history of hospital-treated infections and community-based anti-infective prescriptions was assessed in population-based registries. We used conditional logistic regression to compute OR of GCA/PMR associated with infections while adjusting for comorbidities, immunosuppressive treatment, and other potential confounders.

RESULTS

We included 7,225 GCA/PMR cases and 72,250 controls. When excluding all infections occurring within the last year before GCA/PMR diagnosis, there was no decreased risk for GCA/PMR in people with a history of hospital-treated infection (adjusted OR=1.04, 95% CI: 0.98-1.10) or community anti-infective treatment (adjusted OR=1.07, 95% CI: 0.99-1.16). Within the last year preceding the GCA/PMR index date, patients with hospital-treated infections (adjusted OR=1.59, 95% CI: 1.44-1.75) or community anti-infective treatment (adjusted OR=1.63, 95% CI: 1.48-1.79) had a greatly increased risk of a GCA/PMR diagnosis.

CONCLUSION

These results do not support the hypothesis of "hyper-immunity" leading to GCA/PMR. Instead, incident GCA/PMR is preceded by a slightly increased risk of infection, which may be related to protopathic bias or support theories that infections may be directly involved in the pathogenesis of GCA/PMR.

摘要

目的

有人提出,高效免疫系统(“超免疫”)是巨细胞动脉炎和风湿性多肌痛(GCA/PMR)发病机制的核心。我们研究了作为超免疫标志物的低感染风险是否能预测随后GCA/PMR风险的增加。

患者与方法

我们进行了一项基于人群的病例对照研究,纳入了1997年至2012年在丹麦北部诊断为初发GCA/PMR的所有≥50岁患者。对于每例病例,我们选择10名在性别、年龄、居住地点和在该地区居住时间上匹配的人群对照。在基于人群的登记处评估医院治疗感染和社区抗感染处方的完整病史。我们使用条件逻辑回归来计算与感染相关的GCA/PMR的比值比,同时调整合并症、免疫抑制治疗和其他潜在混杂因素。

结果

我们纳入了7225例GCA/PMR病例和72250名对照。在排除GCA/PMR诊断前最后一年内发生的所有感染后,有医院治疗感染史的人患GCA/PMR的风险没有降低(调整后的比值比=1.04,95%可信区间:0.98-1.10),接受社区抗感染治疗的人也是如此(调整后的比值比=1.07,95%可信区间:0.99-1.16)。在GCA/PMR索引日期前的最后一年内,有医院治疗感染史的患者(调整后的比值比=1.59,95%可信区间:1.44-1.75)或接受社区抗感染治疗的患者(调整后的比值比=1.63,95%可信区间:1.48-1.79)被诊断为GCA/PMR的风险大大增加。

结论

这些结果不支持“超免疫”导致GCA/PMR的假说。相反,在发生GCA/PMR之前,感染风险略有增加,这可能与原发病偏倚有关,或支持感染可能直接参与GCA/PMR发病机制的理论。

相似文献

2
Serious infections in people with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA): a time-trend national US study.
Clin Rheumatol. 2020 Nov;39(11):3427-3438. doi: 10.1007/s10067-020-05129-w. Epub 2020 May 12.
3
Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis.
Ann Rheum Dis. 2005 Dec;64(12):1765-8. doi: 10.1136/ard.2005.036459. Epub 2005 Apr 20.
6
Giant cell arteritis or polymyalgia rheumatica after influenza vaccination: A study of 12 patients and a literature review.
Autoimmun Rev. 2021 Feb;20(2):102732. doi: 10.1016/j.autrev.2020.102732. Epub 2020 Dec 14.
7
Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015.
Semin Arthritis Rheum. 2017 Oct;47(2):253-256. doi: 10.1016/j.semarthrit.2017.04.001. Epub 2017 Apr 7.
8
Associations between polymyalgia rheumatica and giant cell arteritis and 12 cardiovascular diseases.
Heart. 2016 Mar;102(5):383-9. doi: 10.1136/heartjnl-2015-308514. Epub 2016 Jan 19.
9
Common co-morbidities in polymyalgia rheumatica and giant cell arteritis: cross-sectional study in UK Biobank.
Rheumatol Adv Pract. 2023 Nov 2;7(3):rkad095. doi: 10.1093/rap/rkad095. eCollection 2023.

引用本文的文献

2
Influenza A infection as a potential trigger of giant cell arteritis: A case report.
SAGE Open Med Case Rep. 2024 Sep 14;12:2050313X241272666. doi: 10.1177/2050313X241272666. eCollection 2024.
4
Giant Cell Arteritis Presenting as Bilateral Cotton Wool Spots.
Cureus. 2022 Oct 1;14(10):e29804. doi: 10.7759/cureus.29804. eCollection 2022 Oct.
5
6
Polymyalgia rheumatica following infective triggers or vaccinations: a different subset of disease?
Reumatologia. 2020;58(2):76-80. doi: 10.5114/reum.2020.95360. Epub 2020 Apr 30.
7
A new era for giant cell arteritis.
Eye (Lond). 2020 Jun;34(6):1013-1026. doi: 10.1038/s41433-019-0608-7. Epub 2019 Oct 3.
8
Pathogenesis, Diagnosis and Management of Polymyalgia Rheumatica.
Drugs Aging. 2019 Nov;36(11):1015-1026. doi: 10.1007/s40266-019-00705-5.

本文引用的文献

1
Autoimmunity in the Elderly: Insights from Basic Science and Clinics - A Mini-Review.
Gerontology. 2017;63(6):515-523. doi: 10.1159/000478012. Epub 2017 Jul 29.
2
Giant cell arteritis, infections and biologics.
Ann Rheum Dis. 2017 Sep;76(9):e29. doi: 10.1136/annrheumdis-2016-210955. Epub 2017 Jan 5.
3
Infections and the risk of incident giant cell arteritis: a population-based, case-control study.
Ann Rheum Dis. 2017 Jun;76(6):1031-1035. doi: 10.1136/annrheumdis-2016-210152. Epub 2016 Nov 28.
5
The Danish National Patient Registry: a review of content, data quality, and research potential.
Clin Epidemiol. 2015 Nov 17;7:449-90. doi: 10.2147/CLEP.S91125. eCollection 2015.
6
Innate immune cells in the pathogenesis of primary systemic vasculitis.
Rheumatol Int. 2016 Feb;36(2):169-82. doi: 10.1007/s00296-015-3367-1. Epub 2015 Sep 24.
7
New insights into the pathogenesis of giant cell arteritis and hopes for the clinic.
Expert Rev Clin Immunol. 2016;12(1):57-66. doi: 10.1586/1744666X.2016.1089173. Epub 2015 Sep 14.
9
Hospitalization rates and utilization among patients with giant cell arteritis: A population-based study from 1987 to 2012.
Semin Arthritis Rheum. 2015 Aug;45(1):70-4. doi: 10.1016/j.semarthrit.2015.02.010. Epub 2015 Mar 3.
10
A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility.
Am J Hum Genet. 2015 Apr 2;96(4):565-80. doi: 10.1016/j.ajhg.2015.02.009. Epub 2015 Mar 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验